Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPLSG STKI-14 study)

Haruko Shima, Akiko Kada, Akihiko Tanizawa, Yuki Yuza, Akihiro Watanabe, Masaki Ito, Hideko Uryu, Katsuyoshi Koh, Chihaya Imai, Nao Yoshida, Yuhki Koga, Naoto Fujita, Akiko M. Saito, Souichi Adachi, Eiichi Ishii, Hiroyuki Shimada

研究成果: Article

1 引用 (Scopus)

抜粋

DISCLOSURES: Kada: Bayer Yakuhin: Other: personal fees for a member of independent data monitoring committee of clinical trials, outside of the submitted work.. Imai:Juno Therapeutics: Patents & Royalties.

元の言語English
ページ数1
ジャーナルBlood
134
発行部数1
DOI
出版物ステータスPublished - 2019 11 13

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

フィンガープリント Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPLSG STKI-14 study)' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Shima, H., Kada, A., Tanizawa, A., Yuza, Y., Watanabe, A., Ito, M., Uryu, H., Koh, K., Imai, C., Yoshida, N., Koga, Y., Fujita, N., Saito, A. M., Adachi, S., Ishii, E., & Shimada, H. (2019). Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPLSG STKI-14 study). Blood, 134(1). https://doi.org/10.1182/blood-2019-122623